Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Current Deferred Revenue (2018 - 2020)

Addex Therapeutics' Current Deferred Revenue history spans 2 years, with the latest figure at $811551.0 for Q4 2020.

  • On a quarterly basis, Current Deferred Revenue rose 385.65% to $811551.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $811551.0, a 385.65% increase, with the full-year FY2020 number at $811551.0, up 385.65% from a year prior.
  • Current Deferred Revenue came in at $811551.0 for Q4 2020, up from $167106.3 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $811551.0 in Q4 2020, with the low at $167106.3 in Q4 2019.